Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
This clinical trial aims to compare the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of plantar warts.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Viral warts represent benign epidermal proliferations associated with human papillomavirus (HPV) infection. HPV is a double-stranded DNA virus with more than 150 identified types, several of which have a predilection for cutaneous tissues and can produce distinct clinical forms of warts. Transmission occurs through direct skin-to-skin contact, indirect contact with contaminated surfaces, or autoinoculation, as when a wart is scratched or picked and virus is carried to a new site.
Cutaneous warts occur worldwide, with an estimated overall population prevalence of roughly 10%, rising to 10-20% among school-aged children. Although warts may develop at any age, incidence climbs through childhood and peaks between 12 and 16 years. Most lesions are asymptomatic, but they are not without consequence: warts can produce cosmetic disfigurement and psychosocial distress, and those on weight-bearing surfaces such as the plantar skin can become painful with walking or pressure. The principal clinical types are common, plantar, plane, filiform, and genital warts.
Plantar warts, the focus of the present study, arise on the sole and are most commonly attributed to HPV types 1, 2, 4, 27 and 57. Because of the constant pressure exerted by weight-bearing, these lesions tend to grow inward rather than outward and are often covered by a thick overlying callus that can mask the lesion and delay diagnosis; adjacent warts may also coalesce into a mosaic pattern. Unlike many other cutaneous warts, plantar warts are frequently symptomatic, producing a sharp, well-localized pain on walking or standing that can meaningfully impair mobility and daily activities. Clinically, they are distinguished from corns and calluses by the presence of pinpoint black dots, corresponding to thrombosed dermal capillaries, and by interruption of the normal skin lines across the lesion.
Several therapeutic modalities are available for cutaneous warts, including destructive methods such as salicylic acid, cryotherapy, silver nitrate, electrosurgery and pulsed-dye laser, antiproliferative agents such as formaldehyde, vitamin D3, bleomycin, 5-fluorouracil, podophyllin and podophyllotoxin, topical immunological agents such as imiquimod ; However, treatment remains challenging because of variable efficacy, prolonged treatment courses, recurrence and adverse effects. No single treatment option is considered gold standard.
Intralesional therapies are an emerging and effective approach for treating recalcitrant warts. Several immunotherapeutic agents for warts including vitamin D3; tuberculin purified protein derivative (PPD); Candida antigen (Candida); the measles, mumps, rubella (MMR) vaccine, BCG, zinc sulphate and antivirals such as acyclovir have demonstrated variable complete response rates in randomized controlled trials. Unlike various other treatment options, immunotherapeutic approaches upregulate the immune system to recognize and destroy the lesions at both the target site and distant locations.
Acyclovir, a synthetic purine nucleoside analogue, is active against herpes simplex virus (HSV) and varicella-zoster virus (VZV) through a selective activation pathway: viral thymidine kinase first converts the drug to its monophosphate form, after which host-cell enzymes complete its conversion to the active triphosphate metabolite. This triphosphate form competitively blocks viral DNA polymerase and, once incorporated into the elongating viral DNA strand, halts further chain extension, thereby arresting viral DNA synthesis.
Acyclovir is considered an evolving treatment option for warts; however, its mechanism of action against HPV is not fully understood. In a recent randomized controlled trial, intralesional acyclovir (70 mg/ml) was injected at a dose of 0.1 ml using an insulin syringe into each of the largest three warts (total 0.3 ml per session), repeated every 2 weeks until complete clearance or for a maximum of five sessions, resulting in a complete response rate of 37.5%.
The therapeutic effect of zinc sulphate in warts is thought to reflect a combination of direct local cytotoxicity and immune stimulation. Following intralesional injection, it triggers a localized inflammatory cascade in which eosinophils arrive first, followed sequentially by lymphocytes and fibroblasts, which may help drive immune-mediated clearance of HPV-infected keratinocytes. Zinc also contributes to immune regulation by supporting leukocyte and natural killer cell function. However, the precise mechanism by which intralesional zinc sulphate promotes HPV clearance remains incompletely understood.
Zinc sulfate has been investigated as an effective intralesional immunotherapy treatment for warts. A recent randomized controlled study evaluated intralesional 2% zinc sulphate in patients with common, plantar, and plane warts. Zinc sulphate was prepared by dissolving 2 g in 100 ml sterile distilled water and autoclaving at 95°C for 20 minutes. A dose of 0.1 ml was injected into the largest wart until blanching or bleb formation, with treatment repeated for up to six sessions. Complete response was achieved in 68.6% of patients, while complete clearance of the target wart was observed in 74.3% of cases.
Although both agents have demonstrated promising efficacy in the treatment of cutaneous warts, so far, there is no direct comparative study evaluating intralesional acyclovir versus intralesional zinc sulphate. Therefore, the present study aims to provide a direct head to head comparison of the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of patients with plantar warts.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Silvana S Shawky, Resident
- Phone Number: 01099029774
- Email: Silvana.18313420@med.aun.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18-50 years of both sexes clinically diagnosed with multiple plantar warts.
Exclusion Criteria:
- Patients with wart types other than plantar warts (genital, common, and plane warts).
- Pregnant or lactating women.
- Immunocompromised patients.
- Individuals receiving systemic immunosuppressive or antiviral therapy.
- History of hypersensitivity to acyclovir or zinc compounds.
- Patients with current acute febrile illness or any bacterial infection.
- Receiving any treatment for warts within 1 month before the study.
- Concurrent other skin disorders.
- Patients with systemic diseases (liver or renal disease, bleeding disorders).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Intralesional Acyclovir
This group will receive intralesional acyclovir |
Intralesional injection of acyclovir, prepared using 250 mg acyclovir vial diluted with 3.5 ml saline (yielding an acyclovir concentration of approximately 70 mg/ml), at a dose of (0.1- 0.3 ml) injected into the largest (target) wart under aseptic precautions using an insulin syringe. The injection will be repeated every 2 weeks until complete clearance of warts or for a maximum of five sessions. |
|
Active Comparator: Intralesional Zinc Sulphate
This group will receive intralesional zinc sulphate 2% |
Intralesional injection of 2% zinc sulphate prepared using 2 gm of zinc sulphate powder dissolved in 100 ml of sterile distilled water and autoclaved at 95°C for 20 minutes, at a dose of (0.1- 0.3 ml) in the base of the largest (target) wart . The wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis. Injections will be repeated for all patients into the same lesion every 2 weeks until complete clearance of warts or for a maximum of five sessions. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Response of the Injected Warts
Time Frame: 8 weeks
|
Clinical response assessed by standardized digital photographs and dermoscopic evaluation. Response will be graded using scoring system : Score 0: neither clinical nor dermoscopic response. Score 1: clinical improvement without dermoscopic clearance. Score 2: clinical disappearance with dermoscopic evidence of residual wart tissue. Score 3: complete clinical and dermoscopic clearance with return of normal skin markings. |
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dalia A Attallah, Professor, Dermatology Department Assiut University Hospital, Assiut, Egypt
- Study Director: Radwa M Bakr, Assistant Professor, Dermatology Department Assiut University Hospital, Assiut, Egypt
Publications and helpful links
General Publications
- Barkat MT, Abdel-Aziz RTA, Mohamed MS. Evaluation of intralesional injection of bleomycin in the treatment of plantar warts: clinical and dermoscopic evaluation. Int J Dermatol. 2018 Dec;57(12):1533-1537. doi: 10.1111/ijd.14092. Epub 2018 Jun 15.
- Youssef EMK, Eissa MAA, Bakr RM. Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts. Arch Dermatol Res. 2023 Jul;315(5):1305-1314. doi: 10.1007/s00403-022-02499-w. Epub 2022 Dec 26.
- Mohamed EE, Tawfik KM, Mahmoud AM. The Clinical Effectiveness of Intralesional Injection of 2% Zinc Sulfate Solution in the Treatment of Common Warts. Scientifica (Cairo). 2016;2016:1082979. doi: 10.1155/2016/1082979. Epub 2016 Mar 31.
- Gharib K, Taha A, Elradi M. Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial. Arch Dermatol Res. 2024 Jun 1;316(6):325. doi: 10.1007/s00403-024-03001-4.
- Mullen SA, Myers EL, Brenner RL, Nguyen KT, Harper TA, Welsh D, Keffer S, Mueller J, Whitley MJ. Systematic Review of Intralesional Therapies for Cutaneous Warts. JID Innov. 2024 Jan 24;4(3):100264. doi: 10.1016/j.xjidi.2024.100264. eCollection 2024 May.
- Al Aboud AM, Nigam PK. Wart. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK431047/
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Disease Attributes
- Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Skin Diseases
- Skin Diseases, Infectious
- Tumor Virus Infections
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Papillomavirus Infections
- Warts
- Skin Diseases, Viral
Other Study ID Numbers
Other Study ID Numbers
- PlantarWarts-RCT-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.